Immuneering reveals positive data from tumour treatment trial
IMM-1-104 found to be well tolerated with no dose limiting toxicities or serious adverse events
Read More
Tag: Immuneering
DDF, Immuneering form $1.3m Alzheimer’s research collaboration
Britain’s Dementia Discovery Fund has formed a research collaboration with US group Immuneering Corporation that aims to identify novel drug targets and candidates for Alzheimer’s disease.
Read More
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
